Anthony A, Amato MD. Intravenous immune globulin therapy in dermatomyositis. N Engl J Med. 2022;387:1320–1.

Article  Google Scholar 

Van de Vlekkert J, Hoogendijk JE, de Haan RJ, et al. Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomized clinical trial. Neuromuscul Disord. 2010;20:382–9.

Article  PubMed  Google Scholar 

Gordon PA, Winer JB, Hoogendijk JE, et al. Immunosuppressive and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev. 2012;8: CD003643.

Google Scholar 

Qushmaq KA, Chalmers A, Esdaile JM. Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review. J Rheumatol. 2000;27:2855–9.

CAS  PubMed  Google Scholar 

Ellman MH, Hurwitz H, Thomas C, Kozloff M. Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. J Rheumatol. 1991;18:1741–3.

CAS  PubMed  Google Scholar 

Kohsaka H, Mimori T, Kanda T, et al. Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. Mod Rheumatol. 2019;29(1):1–19.

Article  PubMed  Google Scholar 

Komatsuda A, Wakui H, Nimura T, Sawada K-I. Reversible infliximab-related lymphoproliferative disorder associated with Epstein-Barr virus in a patient with rheumatoid arthritis. Mod Rheumatol. 2008;18(3):315–8.

Article  CAS  PubMed  Google Scholar 

Tokuhira M, Tamaru J-I, Kizaki M. Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders. J Clin Exp Hematopathol. 2019;59(2):72–92.

Article  Google Scholar 

Cheson BD, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68.

Article  PubMed  PubMed Central  Google Scholar 

Yasuo Suzuki et al. https://mhlw-grants.niph.go.jp/system/files/report_pdf/202013002A%20--buntan2_0.pdf

Kurita D, et al. Methotrexate-associated lymphoproliferative disorders in patients with rheumatoid arthritis: clinicopathologic features and prognostic factors. Am J Surg Pathol. 2019;43:869–84.

Article  PubMed  Google Scholar 

Tokuhira M, et al. Clinicopathlogic investigation of methotrexate-induced lymphoproliferative disorders, with a focus on regression. Leuk Lymphoma. 2018;59:1143–52.

Article  CAS  PubMed  Google Scholar 

Sekiguchi Y, Shimada A, Imai H, et al. Epstein-Barr virus-negative, CD5-positive diffuse large B-cell lymphoma developing after treatment with oral tacrolimus for mixed connective tissue disease : a case report and review of the literature. J Clin Exp Hematopathol. 2012;52(3):211–8.

Article  Google Scholar 

Dubey S, Adebajo AO. Lymphoproliferative disorder due to sulphasalazine. Case Reports. 2009. https://doi.org/10.1136/bcr.06.2008.0038. (Published online 2009 Mar 17).

Article  Google Scholar 

Suzuki Y, Chinen N. Treatment of rheumatic diseases: current status and future prospective. Topics: II. Immunosuppressant/antirheumatic drugs; 1. Methotrexate. J Jpn Soc Intern Med. 2011;100(10):2902–9.

Article  CAS  Google Scholar 

Satou A, Nakamura S. EBV-positive B-cell lymphomas and lymphoproliferative disorders: review from the perspective of immune escape and immunodeficiency. Cancer Med. 2021;10(19):6777–85.

Article  PubMed  PubMed Central  Google Scholar 

Ichikawa A, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histrogy, Epstein-Barr virus, and clonarity are important predictors of disease progression and regression. Eur J Haematol. 2013;91:20–8.

Article  CAS  PubMed  Google Scholar 

Kuramoto N, et al. Characteristics of rheumatoid arthritis with immunodeficiency-associated lymphoproliferative disorders to regress spontaneously by the withdrawal of methotrexate and their clinical course: a retrospective, multicenter, case-control study. Mod Rheumatol. 2022;32:24–31.

Article  PubMed  Google Scholar 

Hashimoto A, Chiba N, Tsuno H, et al. Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population. J Rheumatol. 2015;42(4):564–71.

Article  CAS  PubMed  Google Scholar 

Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational study. Lancet. 2009;374:1617–25.

Article  CAS  PubMed  Google Scholar 

Toyama S, Takatani A, Koga T, et al. Gastric perforation due to iatrogenic immunodeficiency-associated lymphoproliferative disorder during the treatment of rheumatoid arthritis. Intern Med. 2019;58:3331–6.

Article  PubMed  PubMed Central  Google Scholar 

Bai Y, He T, Zhang L, et al. Prognostic value of FOXP3+ regulatory T cells in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis. BMJ Open. 2022;12: e060659.

Article  PubMed  PubMed Central  Google Scholar 

Smith MA, Irving PM, Marinaki AM, Sanderson JD. Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. Aliment Pharmacol Ther. 2010;32(2):119–30.

Article  CAS  PubMed  Google Scholar 

Kameda H, Yamaoka K, Yamanishi Y, et al. Japan College of Rheumatology guidance for the use of methotrexate in patients with rheumatoid arthritis: secondary publication. Mod Rheumaol. 2023. https://doi.org/10.1093/mr/road098. (Online ahead of print).

Article  Google Scholar 

Mahadevan U, Dubinsky MC, Su C, et al. Outcomes of pregnancies with maternal/paternal exposure in the tofacitinib safety databases for ulcerative colitis. Inflamm Bowel Dis. 2018;24(12):2494–500.

Article  PubMed  PubMed Central  Google Scholar